See the latest news and media coverage for Definium Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Psychedelic medicine company for brain health disorders
definiumtx.comLast updated
In short: Definium Therapeutics reported positive Phase 3 results for its LSD-based therapy DT120 in depression and anxiety and raised $805 million.
The milestone follows positive Phase 3 trial results showing significant symptom improvement for major depressive disorder, marking the drug's second FDA breakthrough designation.
The study met primary and key secondary endpoints, with a 5.4-point placebo-adjusted HAM-A reduction at Week 12 and no new safety signals.
Positive Phase 3 Emerge data for DT120 ODT in major depressive disorder were disclosed, with cash and investments at about $1.1 billion.
CEO Robert Barrow discusses positive Emerge results and the company's commitment to advancing mental health treatments
Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric...
On September 8, 2026, Definium Therapeutics received a second Breakthrough Therapy designation from the FDA for DT120 (lysergide) orally disintegrating tablet, this time for major...
Detailed price information for Definium Therapeutics Inc (DFTX-Q) from The Globe and Mail including charting and trades.
DT120 (lysergide) hits all endpoints in phase 3 GAD trial, cutting anxiety scores with a single...
Track Definium Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Definium Therapeutics and other trending companies.